entity_name,head_count,tail_count,labels
gut microbiota,62,18,"['Microbiota', 'biological entity', 'MicrobialCommunity', 'Microorganism', 'Biological process', 'microbial community', 'Biological Entity', 'Organism', 'microbiota', 'Microbial Community', 'Physiological Parameter']"
Probiotics,27,0,"['Substance', 'Therapeutic agent', 'Therapeutic Agent']"
Gut microbiota,24,6,"['Microbiota', 'Biological Process', 'Microbial_Ecosystem', 'Microorganism', 'Biological entity', 'Biological Entity', 'Microbial Community']"
gut-brain axis,19,2,"['physiological system', 'Biological Process', 'biological system', 'biological concept', 'Biological Concept']"
post-COVID-19 DGBI,19,1,['Disorder']
Parkinson's disease,18,19,"['Disease', 'disease', 'neurodegenerative disease']"
Melanin,17,0,['Substance']
Triphala polyphenols,15,0,['Substance']
probiotics,13,2,"['Food', 'Substance', 'microbial treatment', 'biological agent', 'Nutrient']"
Ruminococcaceae,13,0,"['Microbial Family', 'microbial family']"
High-fiber diet,13,0,['Diet']
High-cholesterol diet,12,0,['Diet']
Helicobacter pylori,12,0,['Organism']
failure in interaction,10,0,['biological dysfunction']
Essential oils,10,0,['Substance']
Butylated Starch,10,0,['Substance']
SBF,9,1,['Chemical compound']
MEs,9,0,['Epitope']
NVP-1704,9,0,['Probiotic']
gut microbiome,9,8,"['Biological Process', 'biological entity', 'Microbiome', 'microbial community', 'Physiological System', 'Biological Entity']"
China,9,0,['Country']
Bacillus licheniformis,9,0,['Probiotic']
Gut Microbiome,9,3,"['BiologicalSystem', 'Microbial Community', 'Biological System']"
Malnutrition,9,0,['Condition']
plant polysaccharides,9,3,['Substance']
Hydrogen sulfide,9,1,['Chemical']
probiotic formula,8,0,['formula']
EDF,8,1,['Treatment']
gut microbial metabolites,8,0,['biochemical molecule']
Fermented Wheat Germs (FWGs),8,1,['Food']
microbiota,8,2,"['Biological Entity', 'microbial community', 'biological entity']"
Schizophrenia,7,7,"['Disease', 'Condition']"
low-dose PHP,7,0,['Substance']
Lactobacillus plantarum CCFM8661,7,0,['Probiotic']
trichloroethylene,7,0,['chemical']
Porphyra haitanensis polysaccharide,7,0,['Substance']
microbiota-gut-brain axis,7,2,"['Biological Process', 'Pathway', 'Biological System']"
RSDS Mice,7,0,['Animal Model']
PwP,7,0,['patient group']
DEGs,6,0,['Genetic Entity']
dysbiosis,6,0,['microbial imbalance']
changes in stability and diversity of gut microbiota,6,0,['microbial changes']
Blautia,6,1,"['genus', 'Gut Microbiota', 'Bacteria', 'bacterial genus', 'bacteria']"
Insomnia,6,1,['Mental Health Issue']
voluntary wheel running,6,0,['activity']
Christensenellaceae,5,1,['Microbial Family']
consumption,5,0,['Behavior']
Prebiotic supplementation,5,0,['Therapeutic Intervention']
PCOS-DP,5,3,['Patient Group']
bin_55,5,0,['microbial strain']
Microbiota composition,5,1,"['Composition', 'Biological Process']"
subdiaphragmatic vagotomy (SDV),5,0,['Medical Procedure']
Loss of melanin,5,0,['Condition']
study,5,0,"['Research', 'research study']"
tryptophan metabolism,5,1,['biological process']
Migraine Headache,5,1,['Medical Condition']
Type 2 diabetes,4,0,['Disease']
Alterations in ATP production,4,0,['Biological process']
Gut bacteria,4,0,['Organism']
translational research,4,1,"['research type', 'research effort']"
Microbiome research,4,0,['Research Field']
Flavonifractor,4,1,['Microbial Genus']
neurodegenerative disorders,4,4,"['disease category', 'Disease', 'disease']"
NAPEs,4,0,['Lipid']
PTSD,4,0,['Mental Health Condition']
Herpesvirus,4,4,['Pathogen']
Dysregulation of Gut Barrier Functions,4,2,['Physiological State']
Haemophilus,4,0,['Bacteria']
Major depression,4,0,['Disease']
Colon cancer-related anemia,4,0,['Disease']
gut-microbiota-brain axis,4,2,"['Biological Process', 'biological system']"
Stress,4,0,['Condition']
Lactobacillus,4,2,"['Microbe', 'Bacteria', 'Genus', 'Probiotic Genus']"
patients after SG,4,0,['Human']
Gut Microbiota,4,3,"['Biological Entity', 'Biological Process', 'Microbial Community', 'Organism']"
Depression,4,5,"['Mental Disorder', 'Disease', 'Condition']"
Triphala,4,0,['Medicine']
high-dose PHP,4,0,['Substance']
F4,4,0,['Probiotic']
Bacteroides,4,1,"['Microbial Taxon', 'microbe', 'bacteria']"
Gut microbiome,4,0,"['Microbial Community', 'Organism']"
canine microbiota,4,0,['microbial community']
Probiotic,4,0,['Intervention']
Autism spectrum disorder (ASD),4,0,"['Disorder', 'Disease']"
Microbiota,4,0,"['Microbiota', 'Biological Entity', 'Gut Microbiota']"
insomnia patients,4,0,['patient group']
PD patients,3,3,['Patient Group']
AD,3,0,['Disease']
Repeated Social Defeat Stress,3,0,['Stress Model']
Parkinson's disease (PD),3,1,['Disease']
microbial dysbiosis,3,0,['Pathological Process']
Vasovagal syncope,3,1,['Medical Condition']
microbial composition,3,0,['biological entity']
Gut dysbiosis,3,1,"['Biological Process', 'Condition']"
Lachnoclostridium,3,0,['Microbial Genus']
Tight Junction Proteins,3,1,['Protein']
brain-gut interactions,3,0,['biological process']
patients,3,4,['Human']
Colon Microbiota,3,0,['Organism']
Akkermansia_muciniphila,3,0,['Bacterial Species']
CSF1R inhibitor,3,0,['Pharmacological Agent']
Gut Microbiota Changes,3,1,"['Biological Process', 'Physiological State']"
flu,3,0,['illness']
flavonoids,3,1,['Chemical compound']
antibiotic use,3,2,['treatment']
maternal immune activation,3,1,['condition']
Cardiac tissue proteome,3,0,['Proteome']
Berberine,3,4,['Substance']
Lactobacillus fermentum PS150,3,1,['Bacterial Strain']
Coprococcus,3,0,"['genus', 'Bacteria']"
Mice,3,0,['Organism']
brain-gut axis,3,0,['biological system']
Functional alterations,3,0,['Alteration']
Polycystic ovarian syndrome,3,0,['Disease']
EDF group,3,0,['Treatment Group']
KEGG analysis,3,0,['methodology']
Affective disorders,3,0,['Disease']
bipolar disorder,3,6,['Disease']
classification,3,0,['Model']
Intermittent Fasting,3,0,['Intervention']
Shotgun metagenomics,3,0,['Method']
Traditional depression treatments,3,0,['Treatment']
GR1009,3,1,['Bacterial Strain']
Faecalibacterium,3,0,"['Bacteria', 'Microbial Genus', 'bacteria']"
C-EPS isolated from PS150,3,0,['Substance']
cuprizone (CPZ),3,0,['Chemical']
future research,3,0,['Research Field']
publications,3,6,['Publication']
time to complete the Stroop-C,2,1,['cognitive task']
Prevotella,2,0,"['Bacteria', 'Microbial Species']"
Botanicals,2,0,['Substance']
plant polysaccharide-based products,2,0,['Product']
Proinflammatory Gut Milieu,2,1,['Physiological State']
standardization,2,0,['Process']
ME composition,2,0,['Epitope composition']
Oral Probiotics,2,0,['Therapeutic Agent']
perturbation of the gut microbiota,2,0,['biological process']
Patients,2,5,"['Human', 'Population']"
Firmicutes,2,0,"['Microbial Taxon', 'Microbial Phylum']"
Sucrose Preference Test,2,0,['Behavioral Test']
3-Dimensional Cultured Crypts,2,0,['Cell Culture']
Intestinal Luminal Contents,2,2,['Biomaterial']
relative abundance,2,1,['Biological Process']
Norepinephrine,2,2,['Neurotransmitter']
microbiota dynamics,2,0,['microbial process']
Intestinal Epithelial Cells,2,0,['Cell Type']
Irritable Bowel Syndrome,2,0,['Disease']
gut microbiota structure,2,0,['Biological Entity']
Listeriolysin O peptide,2,0,['Peptide']
multiomics study,2,0,['Research Method']
interactions,2,0,['Process']
acute/chronic insomnia-related bacteria,2,0,['bacteria']
maternal vaginal microbiota,2,0,['microbiota']
infant nasal microbiota,2,0,['microbiota']
Bifidobacteria,2,1,"['Microorganism', 'bacteria', 'bacterial genus']"
Bifidobacterium,2,3,"['Microbial Taxon', 'Bacteria', 'Probiotic', 'bacterial genus', 'Microbe']"
Prebiotics,2,0,['Therapeutic agent']
gut microbiome composition,2,0,['Biological Entity']
shotgun metagenomic sequencing,2,0,"['Sequencing Method', 'Method']"
stool samples,2,1,['Sample']
probiotic supplementation,2,1,['Therapeutic Method']
gut microbiota alterations,2,0,['Biological Change']
Probiotic NVP-1704,2,0,['Probiotic']
micronutrient supplementation,2,0,['Nutrient']
interventions,2,0,['Intervention']
Danggui Buxue Decoction (DBD),2,0,['Medicine']
CCRA model,2,0,['Model']
Microflora metabolites,2,0,['Metabolite']
Clostridium,2,0,"['genus', 'bacterial genus']"
Random Forest classifier,2,0,['Machine Learning Model']
Parabacteroides,2,1,"['Bacteria', 'Gut Microbiota']"
Lactobacillus reuteri ATG-F4,2,0,['Bacteria']
Rodent Models,2,1,['Experimental Model']
Gut,2,1,"['AnatomicalStructure', 'Organ', 'Anatomical Structure']"
microglial activation,2,2,"['Cellular Process', 'Pathological Process']"
disturbances,2,0,['system disturbance']
gut-liver axis,2,0,['PhysiologicalProcess']
medicinal herbs,2,0,['herbal treatment']
metabolic products of dysregulated bacteria,2,0,['biological products']
demyelination,2,4,['Pathological Process']
irritable bowel syndrome (IBS),2,0,['gastrointestinal disease']
targeted therapeutic strategies,2,0,['therapeutic approach']
ED and EDF groups,2,0,['Treatment Groups']
Autoimmunity,2,0,['Condition']
Chronic diseases,2,0,['Disease']
Co-morbid GI inflammation,2,0,['Condition']
GI inflammation,2,1,"['Physiological Mechanism', 'Condition']"
diet,2,0,['Environmental Factor']
Dietary modifications,2,0,['Intervention']
Plasma,2,0,['Biological fluid']
Probiotic supplementation,2,0,['Therapeutic Intervention']
Study,2,0,['Research']
prebiotic feeding,2,0,['Intervention']
intestinal microbiota alterations,2,1,['Condition']
Lactobacillus plantarum,2,0,['Bacteria']
single-cell RNA-seq analysis,2,0,['Analytical Technique']
Influenza infections,2,0,['Infection']
Anaerostipes,2,0,['Gut Microbiota']
prebiotic high-fiber diet,2,0,['Diet']
"holistic, systems-based perspective",2,1,['conceptual framework']
Inflammatory Cytokines,2,1,['Protein']
fecal levels of short-chain fatty acids,2,0,['Biological Marker']
more translational research,2,0,['research effort']
Correlation analysis,2,0,['Analysis']
Diversity of microbiota,2,0,['Biological Metric']
heat-killed PS150,2,0,['Bacterial Strain']
Gut microbiota analysis,2,0,['Analysis']
Gut Microbiomes,2,0,['Organism']
Chronic alcohol overconsumption,2,1,['Condition']
research,2,0,['Research Activity']
Ruminococcus-2,2,0,['Gut Microbiota']
tryptophan transportation,2,0,['biological process']
oral bacteria,2,0,['Biological Entity']
neurological diseases,2,1,['disease']
Inflammation,2,7,"['Biological_Process', 'Biological Process', 'Pathological Process', 'Biological process', 'Condition', 'Physiological State']"
Lachnospiraceae,2,1,"['Microbial family', 'Microbial Family', 'microbial family']"
patients after RYGB,2,0,['Human']
L. plantarum P30025,2,1,['strain']
L. brevis P30021,2,1,['strain']
Toll-like receptor 2,2,0,['Protein']
healthy prenatal diet,2,0,['dietary factor']
Tremors predominant phenotype,2,0,['Clinical Phenotype']
Clinical trials,2,0,['Research Method']
Toll-like receptor 2 signaling pathways,2,1,['Biological Process']
tryptophan transport,2,1,['biological process']
Neuroactive compounds,2,0,['Chemical']
chronic gut dysfunction,2,0,['Pathological Process']
Gut commensal bacteria,2,0,['Organism']
Mayo Clinic,2,0,['Institution']
Toll-like receptor 4 signaling pathways,2,1,['Biological Process']
maternal prenatal gut microbiota,2,0,['biological factor']
Romboutsia,2,0,['microbial species']
Disturbance to gut microbiota,2,0,['Condition']
food processing,2,0,['Process']
Toll-like receptor 4,2,0,['Protein']
dietary interventions,2,0,['therapeutic strategy']
acetate deficiency,2,0,['State']
Oral microbiota,2,0,['Microbiota']
vancomycin,2,0,['Chemical']
Seabuckthorn,2,0,['Plant']
Gut-brain pathways,2,0,"['Physiological Pathway', 'Pathway']"
Intestinal microbiome,2,0,['Microbiome']
microbiota-based approaches,1,1,['therapeutic approach']
Abnormal crypt foci,1,0,['Pathological_Feature']
β-glucuronidase,1,0,['Enzyme']
LBD,1,0,['Disease']
Short-chain fatty acids,1,0,['Biochemical_Substance']
effective treatment,1,1,['Treatment']
DNA methylation,1,1,"['Epigenetic_Process', 'biological process']"
microbial metabolites,1,0,['chemical compound']
data science techniques,1,0,['Technique']
Energy from ATP,1,0,['Energy']
16s rRNA sequencing technique,1,0,['Sequencing Method']
PubMed,1,0,['Database']
Colonic microbiota,1,0,['Microbiota']
Jangi et al study,1,0,['Study']
Fecal Microbiota Transplant,1,1,['Medical Procedure']
Brain-gut Axis,1,0,['Physiological System']
Miyake et al study,1,0,['Study']
Jun Yu,1,0,['Person']
Predominant bacteria,1,0,['Biological Entity']
Ruminococcaceae Incertae Sedis,1,1,['Microbial Taxon']
running exercises,1,1,['activity']
Fear of cancer recurrence,1,0,['Psychological Disorder']
Web of Science Core Collection,1,1,['Database']
CiteSpace,1,0,['Software']
LEfSe analysis,1,1,['Analytical Method']
Microbiome Profiling,1,2,['Biological Process']
Vitiligo,1,2,['Disease']
VOSviewer,1,0,['Software']
Gastrointestinal,1,0,['Biological System']
Disrupted biological pathways,1,0,['Biological Process']
biological aging,1,2,['Biological Process']
Antidepressant Treatment,1,0,['Therapeutic Intervention']
neuroinflammation,1,4,"['biological process', 'Neurobiological Process', 'Pathological Process']"
Bias Assessment,1,0,['Research Methodology']
Systematic Review,1,0,['Research Methodology']
PD,1,0,['Disease']
Biomarkers,1,0,['Biological_Marker']
oral ingestion,1,0,['process']
pro-inflammatory state,1,1,['Biological State']
Corynebacterium,1,1,['Microbial Taxon']
Dietary Supplements,1,1,['Product']
Food,1,1,['Product']
gut microbiome alterations,1,1,"['physiological change', 'Physiological Change']"
Improving Living Standard,1,1,['Social Indicator']
Actinobacteria,1,0,['Microbial Phylum']
anxiety,1,3,"['Mental Disorder', 'Disease', 'Condition']"
depression,1,10,"['Disease', 'Mental Health Condition', 'mental disorder', 'disease', 'Condition']"
hypothalamic-pituitary-ovarian axes,1,0,['Biological Process']
hypothalamic-pituitary-adrenal axes,1,0,['Biological Process']
abnormal levels of neurotransmitters,1,0,['Physiological State']
findings,1,0,['research outcome']
Modernization,1,1,['Process']
Populations at risk,1,0,['Population']
McDonald et al study,1,0,['Study']
Oregano,1,0,['Plant']
Current study,1,0,['Research Study']
changes in gut microbiome,1,1,['Microbial Change']
Alternative tools,1,0,['Therapeutic Tool']
Pathophysiological mechanisms,1,0,['Pathophysiological Mechanism']
Alteration of melanin levels,1,0,['Condition']
microbiome-brain connections,1,0,['Biological Concept']
treatment role,1,0,['Role']
diversity,1,0,['Attribute']
Micronutrient treatment,1,0,['Therapeutic Intervention']
Thyme,1,0,['Plant']
Intervention strategies,1,0,['Therapeutic Strategy']
Gut Microbiota Metabolites,1,0,['Biochemical Process']
Plaques,1,0,['Pathological feature']
Chronic Unpredictable Mild Stress (CUMS) Model,1,0,['Model']
gut microbe,1,1,['Microbial Community']
probiotic,1,0,['Substance']
Short-Chain Fatty Acid Butyrate,1,1,['Chemical Compound']
Gnotobiotic murine model,1,0,['Model']
genus level taxonomy,1,0,['Taxonomic Level']
Microbiome changes,1,0,['Biological Process']
characteristics,1,0,['Attribute']
Gamma-aminobutyric acid (GABA),1,1,['Chemical']
specific bacterial changes,1,0,['Microbial Change']
Food Fermentation,1,0,['Process']
KEGG pathways,1,0,['Pathway Analysis']
Fermented Wheat Germ,1,0,['Food']
Economic Open-ups,1,1,['Event']
Increased Food Intake,1,0,['Behavior']
Antidepressants,1,2,['Medication']
abundance,1,0,['Attribute']
5-HT,1,1,['Neurotransmitter']
Regulating melanin levels,1,0,['Therapeutic intervention']
Pharmacomicrobiomics,1,0,['Scientific Field']
5-HT receptor HTR2A,1,0,['Receptor']
Decreased Exercise,1,0,['Behavior']
Body-First Progression,1,1,['ProgressionType']
Brain-First Progression,1,1,['ProgressionType']
Future Microbiome Research,1,0,['ResearchArea']
Chemotherapy,1,0,['Medical Treatment']
Faecalibaculum,1,1,['MicrobialTaxon']
Roseburia,1,1,"['Microorganism', 'genus']"
microbial tryptophan (Trp) biosynthesis and metabolism pathway (MiTBamp),1,0,['Pathway']
Improvement In Gut Microbiota,1,0,['Therapeutic Outcome']
Muribaculaceae,1,1,['MicrobialTaxon']
Brain⁻gut axis,1,0,['Biological System']
Probiotics regimen,1,0,['Treatment regimen']
Non-tremors predominant phenotype,1,0,['Clinical Phenotype']
Prebiotics and probiotics,1,0,['Therapeutic agents']
"Double-blind, randomized, placebo-controlled trials",1,0,['Trial type']
microbial taxa,1,1,['biological entity']
Abnormal microbiota,1,0,['Condition']
Microbiota⁻gut⁻brain dysfunction,1,0,['Condition']
Correcting disturbance,1,0,['Action']
Patients with ASD,1,0,['Patient group']
Gut microbiota modulation,1,0,['Treatment']
central nervous system,1,3,"['Physiological System', 'nervous system', 'Anatomical Structure']"
Maintaining normal gut microbiota,1,0,['Action']
Restoring normal gut microbiota,1,0,['Action']
Endocrine system,1,0,['System']
ED,1,0,['Treatment']
Brain-gut axis,1,0,['Physiological System']
Gut microbial composition,1,0,['Microbial Community']
Bacterial taxa,1,0,['Organism']
gut microbiota shifts,1,0,['Biological Process']
Abnormal intestinal metabolites,1,0,['Metabolite']
exogenous acetate supplement,1,0,['Treatment']
Gut-brain axis,1,1,"['Physiological Axis', 'Physiological System']"
Gut Microbial Changes,1,0,['Biological Change']
vagal inhibition,1,0,['Biological Process']
gut-brain microbiota axis,1,0,['Biological Process']
mental health symptoms,1,0,['Symptom']
Anxiety,1,0,['Mental Disorder']
Htr1a,1,1,['Gene']
oral microbiota,1,0,['Biological Entity']
gut microbiota composition,1,4,"['Biological Process', 'Biological Data', 'biological entity']"
AAV-shRNA,1,0,['Biological Tool']
oral microbiota imbalance,1,0,['Biological Entity']
Htr1a Downregulation,1,0,['Gene Expression Change']
RF classification,1,0,['Model']
K01626 abundance,1,0,['Genomic Data']
"Four KEGG orthologies (KOs) (K01817, K11358, K01626, K01667) abundances",1,0,['Genomic Data']
Actinobacteria abundance,1,0,['Microbial Abundance']
Bacteroidetes abundance,1,0,['Microbial Abundance']
psychiatric disorders,1,6,"['Disease', 'disease', 'mental health condition']"
3-dehydrocarnitine,1,0,['Metabolite']
EPS,1,0,['Substance']
epiandrosterone sulfate,1,0,['Metabolite']
crude extract containing EPS (C-EPS) from PS150,1,0,['Substance']
leucine,1,0,['Metabolite']
vagus nerve,1,0,['Anatomical Structure']
Brain,1,3,"['AnatomicalStructure', 'Organ', 'Anatomical Structure']"
comparative genomics analysis,1,0,['Method']
exopolysaccharide (EPS),1,0,['Substance']
taxon-function analysis,1,0,['research method']
PS150,1,2,['Bacterial Strain']
microbiota diversity,1,0,['biological diversity']
A. muciniphila,1,1,['microbial species']
multi-omics analysis,1,0,['research method']
Exopolysaccharide,1,0,['Substance']
Compositional alterations,1,0,['Alteration']
brain disorders,1,0,['Disease']
V4 16S rRNA Gene Sequencing,1,0,['Laboratory Technique']
neuroscience,1,0,['Scientific Field']
Colorectal cancer,1,0,['Disease']
human microbiota,1,0,['Biological Entity']
United States,1,0,['Country']
brain,1,3,"['Biological Entity', 'biological structure', 'biological organ', 'Organ']"
Gut microbiota profile,1,0,['Biological Process']
fecal microbiota analysis,1,0,['research method']
Sanada et al. (2020),1,0,['Research Group']
meta-analysis,1,1,['Research Methodology']
participants with MDD,1,0,['Patient Group']
Immune system,1,1,"['System', 'Biological process']"
Microbial genes,1,0,['Genes']
CCDC173,1,0,['Gene']
CREB3L3,1,0,['Gene']
papers,1,0,['Research Publications']
HRSD,1,0,['Assessment Tool']
BDI,1,0,['Assessment Tool']
RNA-seq,1,0,['Method']
genus_Eubacterium (xylanophilum group),1,0,['Gut Microbiota']
We,1,0,['Research Group']
Multiple sclerosis (MS),1,0,['Disease']
genus_Ruminococcaceae (UCG009),1,0,['Gut Microbiota']
Obstructive Sleep Apnea,1,9,['Disease']
genus_Subdoligranulum,1,0,['Gut Microbiota']
mental functioning,1,0,['Condition']
Family_Ruminococcaceae,1,0,['Gut Microbiota']
Transcriptome Sequencing (RNA-seq),1,0,['Method']
genus_Coprococcus2,1,0,['Gut Microbiota']
Metagenomic Sequencing,1,0,['Method']
genus_Eggerthella,1,0,['Gut Microbiota']
Metabolic pathways,1,1,"['Pathway', 'Metabolism']"
Bacteroides eggerthii,1,0,['Microbial Species']
maternal vaginal microbial transfer,1,0,['process']
Microbial metabolites,1,0,['Metabolite']
"vaginally delivered, fully breastfed infants",1,0,['infants']
inflammation,1,2,"['biological process', 'Condition']"
Caesarean section delivery,1,0,['delivery mode']
transfer of maternal rectal microbiota,1,0,['process']
transfer of maternal vaginal microbes,1,0,['process']
maternal rectal microbiota,1,0,['microbiota']
Lachnospira,1,0,['bacteria']
genomic signatures,1,0,['Genomic Entity']
Abundance of Haemophilus,1,0,['Bacterial Abundance']
isomaltose,1,0,['Metabolite']
SARS-CoV2 infection,1,0,['Infection']
maltotriose,1,0,['Metabolite']
patients with COVID-19,1,0,['Patient Group']
urease accessory proteins UreE (COG2371),1,0,['Functional Gene']
fucose permease (COG0738),1,0,['Functional Gene']
post-COVID-19 IBS,1,1,['Disorder']
Trehalose and maltose hydrolase (COG1554),1,0,['Functional Gene']
Enterobacter cloacae,1,0,['Microorganism']
Escherichia coli,1,0,['Microorganism']
anandamide,1,0,['Metabolite']
certain temperaments,1,0,['personality trait']
tryptamine,1,0,['Chemical']
coronavirus disease (COVID)-19,1,0,['Disease']
co-abundances,1,0,['Biological Process']
Alterations in gut microbiota,1,1,['Microbial Alteration']
severe acute respiratory syndrome coronavirus-2 (SARS-CoV2),1,0,['Virus']
tyramine,1,0,['Chemical']
life adversity during childhood,1,0,['life event']
GI infections,1,0,['Infection']
β-phenylethylamine,1,0,['Chemical']
neurodegenerative diseases,1,2,['Disease']
fermented foods,1,0,['Food']
Prevotellaceae,1,0,['Bacteria']
Toll-like receptor 4 dysfunction,1,0,['Pathological Process']
bariatric surgery,1,0,['medical procedure']
Akkermansia,1,0,['Bacteria']
Verrucomicrobiaceae,1,0,['Bacteria']
Toll-like receptor 2 dysfunction,1,0,['Pathological Process']
multiple system atrophy,1,2,['Disease']
altered gut microbiota,1,3,['microbial community state']
microbiota-targeted therapies,1,0,['therapeutic strategy']
high taxonomic resolution,1,1,['Process']
Forced Swim Test,1,0,['Behavioral Test']
Elevated Plus Maze,1,0,['Behavioral Test']
Chronic Mild Stress (CMS),1,1,['Stress Model']
Bifidobacterium longum R0175,1,0,['Probiotic Strain']
Lactobacillus plantarum R1012,1,0,['Probiotic Strain']
improved eating habits,1,0,['Behavior']
Lactobacillus helveticus R0052,1,0,['Probiotic Strain']
bin_31,1,1,['microbial strain']
16S rRNA sequencing,1,1,"['sequencing_technology', 'Methodology']"
fatty acid,1,0,['metabolite']
alpha diversity,1,2,"['Scientific Measurement', 'microbiota characteristic']"
PICRUSt analysis,1,0,['bioinformatics_analysis']
12 significant microbiota biomarkers,1,0,['biomarkers']
Well-designed clinical trials,1,0,['Research Method']
bin_32,1,1,['microbial strain']
Methanobrevibacter,1,0,['genus']
Klebsiella,1,1,"['Microbe', 'genus']"
Proteobacteria,1,0,['phylum']
Collinsella,1,0,['genus']
Megasphaera,1,0,['genus']
Succinivibrio,1,0,['genus']
vitamin B6,1,0,['metabolite']
gut microbial composition,1,0,['microbial structure']
monosaccharide glucose,1,0,['Biological Molecule']
structure -4-α-Glcp-(1→,1,0,['Chemical Structure']
class Negativicutes,1,0,['Taxonomic Class']
genus Clostridiuminnocuumgroup,1,0,['Taxonomic Genus']
obesity,1,2,"['Disease', 'disorder', 'health condition']"
genus Dorea,1,0,['Taxonomic Genus']
Toll-like receptors,1,0,['Protein']
host metabolism,1,2,"['Biological Process', 'physiological process']"
genus Lachnoclostridium,1,0,['Taxonomic Genus']
Interferon-γ,1,0,['Cytokine']
genus Prevotella7,1,0,['Taxonomic Genus']
order Selenomonadalesare,1,0,['Taxonomic Order']
intestine,1,0,['anatomical structure']
Gut Microbiota-Inflammation Axis,1,0,['Physiological Axis']
Illumina sequencing,1,0,['methodology']
geographic location,1,0,['location']
microbiota composition,1,1,"['Biological Process', 'composition']"
"Indoleamine 2,3-Dioxygenase-1",1,0,['Enzyme']
Tumor Necrosis Factor-α,1,0,['Cytokine']
Enhancing stress resilience,1,0,['Strategy']
SHIME®,1,1,['simulator']
health food supplement,1,1,['Food product']
postbiotics,1,0,['Substance']
Mixed phenotype,1,0,['Clinical Phenotype']
glaucoma,1,1,['Disease']
brain cortical thinning,1,1,['Condition']
hyperhomocysteinemia,1,1,['Condition']
exercise,1,1,['activity']
melatonin,1,0,['Chemical']
Toxoplasma gondii,1,0,['Pathogen']
microglia,1,1,['Cell Type']
Inflammatory processes,1,0,['Biological Process']
fiber-rich diet,1,0,['Diet']
Innate immunity,1,1,['Immune Response']
Traumatic Stress,1,0,['Stress Type']
gamma-aminobutyric acid (GABA),1,0,['Chemical']
serotonin,1,0,['Chemical']
dietary microbial metabolites,1,0,['Substance']
Intestinal Flora,1,1,['Biological Entity']
Coliform,1,0,['Microbial Taxon']
Metabolic Assessments,1,0,['Assessment Type']
Olanzapine,1,0,['Medication']
Adverse Reactions,1,0,['Event']
Seabuckthorn flavonoids,1,0,['Chemical compound']
Placebo,1,0,['Control']
Metabolic Syndrome,1,0,['Disease']
PIGD phenotype,1,0,['Clinical Phenotype']
prebiotics,1,2,"['Substance', 'Food', 'biological agent']"
Gastrointestinal disorders,1,1,['Condition']
N-acylphosphatidyl ethanolamines (NAPEs),1,0,['Lipid']
Wheat gluten,1,0,['Substance']
intestinal bacteria,1,0,['Organism']
Nutraceutical interventions,1,0,['Intervention']
dietary fibers,1,1,['Substance']
Bovine milk casein,1,0,['Substance']
Gut microbiota composition,1,0,['Biological entity']
Paired box protein Pax-3 (PAX3),1,0,['Protein']
<i>Frontiers in Psychiatry</i>,1,0,['Journal']
Eyes absent homolog 1 isoform 4 (EYA1),1,0,['Protein']
kynurenine,1,1,"['Chemical', 'Metabolite']"
flavonoid-enriched fraction,1,0,['Chemical compound']
Evans,1,0,['Author']
Repeated Social Defeat Stress (RSDS) Mice,1,0,['Animal Model']
Gut Dysbiosis,1,1,"['Condition', 'Physiological State']"
Journal of Psychiatric Research,1,0,['Journal']
substantia nigra,1,0,['Brain Region']
gut microbiome of ASO mice,1,0,['Physiological System']
Gut Barrier Integrity,1,0,['Physiological Function']
norepinephrine,1,1,"['Chemical', 'Neurotransmitter']"
prebiotic treatment,1,0,['Treatment']
histamine,1,0,['Chemical']
Immigrant status,1,0,['Demographic Factor']
Posttraumatic Stress Disorder (PTSD),1,0,['Mental Health Condition']
anti-anxiety drugs,1,0,['Medication']
Bipolar Disorder,1,0,['Disease']
dopamine,1,1,"['Chemical', 'Neurotransmitter']"
kynurenic acid,1,0,['Chemical']
Gap junction alpha-1 (GJA1),1,0,['Protein']
antidepressant drugs,1,0,['Medication']
Zhejiang University,1,0,['Institution']
Shaohua Hu,1,0,['Author']
Complement C1q,1,0,['Protein']
distinguish gut microbiota differences,0,1,['biological analysis']
PPARg,0,1,['Gene']
butyric acid,0,2,['BiochemicalSubstance']
Viral respiratory infections,0,1,['Disease']
Intestinal metabolites,0,1,['Metabolite']
fatty acid oxidation Acacb,0,1,['GeneticEntity']
WoSCC's literature analysis tool,0,1,['Software']
VOSviewer 1.6.16,0,1,['Software']
high-cited document,0,2,['Publication']
fatty acid transporter CD36,0,1,['GeneticEntity']
liver cell damage,0,1,['PhysiologicalCondition']
physical health effects,0,1,['health outcome']
mental deterioration,0,1,['Condition']
low-density lipoprotein cholesterol,0,1,['PhysiologicalParameter']
illness severity,0,1,['Condition']
microbiota composition modification,0,1,['Biological Process']
time to complete the Stroop-CW,0,1,['cognitive task']
repeated animal words in 60 s,0,1,['cognitive task']
lipid metabolism,0,1,['PhysiologicalProcess']
mouse model of Parkinson's,0,1,['Animal Model']
Fasn,0,1,['Gene']
Me1,0,1,['Gene']
Parkinson's disease patients,0,3,"['Disease', 'Patient']"
Abhd5,0,1,['Gene']
fatty acid transport genes,0,1,['GeneticEntity']
Intestinal microflora,0,1,['Microbial Community']
Pnpla3,0,1,['Gene']
Psychosis,0,4,['Disease']
correct answers in 120 s on the Stroop-CW,0,1,['cognitive task']
Elovl6,0,1,['Gene']
patients with MDD,0,3,['patient group']
triglyceride metabolites,0,1,['BiochemicalSubstance']
host metabolic pathways,0,1,['biological process']
phosphatidylcholine metabolites,0,1,['BiochemicalSubstance']
bibliometric analysis,0,2,['Method']
Neuroinflammatory disorders,0,1,['Disease']
Respiratory infections,0,1,['Disease']
gender,0,1,['demographic characteristic']
psychophysiological stress reactivity,0,1,['physiological response']
constipation,0,1,['symptom']
gastrointestinal medication use,0,1,['treatment']
upregulated metabolic pathways,0,1,['biological process']
downregulated metabolic pathways,0,1,['biological process']
whole grain cereals,0,1,['Food']
Symbiosis,0,1,['Relationship']
Clostridium difficile colitis,0,1,['infectious disease']
Behavioral Effects,0,1,['Behavioral Outcome']
future therapeutic strategies,0,1,['treatment']
autonomic nervous system dysregulation,0,1,['biological process']
reduced functional activation of the hippocampus,0,1,['biological process']
increased Proteobacteria,0,1,['biological entity']
anxiety-like behaviors,0,1,['behavior']
Inflammatory conditions,0,1,['Disease']
metabolic syndrome,0,1,['health condition']
Type 2 diabetes mellitus,0,1,['health condition']
Immune dysfunction,0,1,['Condition']
Psychiatric Disorders,0,2,['Disease']
Neurological Disorders,0,2,['Disease']
gut microenvironment,0,1,['biological environment']
gut microbial community structure,0,1,['microbial community state']
Symbiotic relationship,0,1,['Relationship']
PRISMA Guidelines,0,1,['Methodological Framework']
Critical function in homeostasis,0,1,['Biological Function']
Studies,0,1,['Research Studies']
Microbiota Changes,0,1,['Biological Process']
Prevotella species,0,1,['microbial species']
Literature Search,0,1,['Research Methodology']
mental health effects,0,1,['health outcome']
functional changes,0,1,['biological function']
triglycerides,0,1,['PhysiologicalParameter']
serum total cholesterol,0,1,['PhysiologicalParameter']
reduced alpha diversity,0,1,['biological characteristic']
overall well-being,0,1,['health aspect']
Gut-lung axis,0,1,['Physiological Axis']
increased Synergistetes,0,1,['biological entity']
hypolipidemic effect,0,2,['PhysiologicalEffect']
functional activities,0,1,['biological process']
environmental ecology,0,1,['environmental system']
gut,0,1,['anatomical structure']
blood,0,1,['biological fluid']
blood lipid,0,1,['PhysiologicalParameter']
brainstem,0,3,['brain region']
Clinical Effects of Antidepressants,0,1,['Therapeutic Outcome']
Lung health,0,1,['Organ Function']
decreased Intestinibacter,0,1,['biological entity']
decreased Kineothrix,0,1,['biological entity']
jejunal expression of pro-inflammatory markers,0,1,['gene expression']
decreased Agathobaculum,0,1,['biological entity']
inferred microbiota function,0,1,['microbiota function']
decreased Roseburia,0,1,['biological entity']
cecal microbiota composition,0,1,['microbiota composition']
running group,0,1,['experimental group']
gut microbial,0,1,['microbial community']
brain inflammatory activity,0,1,['physiological process']
Gut Microbiota Composition,0,1,['Biological Process']
grooming patterns,0,1,['behavior']
Activation of the immune system,0,1,['Biological Process']
Bioavailability of Antidepressants,0,1,['Pharmacokinetic Process']
decreased Colidextribacter,0,1,['biological entity']
host health,0,1,['Health']
depressive behaviour,0,1,['Mental Disorder']
α-synuclein aggregation in the vagus nerve,0,1,['Pathological Process']
CAD,0,1,['Disease']
T2DM,0,1,['Disease']
Gastrointestinal (GI) problems,0,1,['Symptom']
ASD,0,2,['Disease']
Immune pathways,0,1,['Pathway']
Inflammation pathways,0,1,['Pathway']
Immune Epitope Database,0,1,['Database']
ASD children,0,3,['Patient group']
Typically developing (TD) children,0,2,['Patient group']
pathogenesis of major depressive disorder,0,1,['disease process']
Abnormal gut IgA levels,0,1,['Physiological condition']
Altered gut microbiota composition,0,1,['Physiological condition']
positive feedback loop for chronic gut dysfunction,0,2,['Pathological Process']
Abnormalities in gut immunity,0,1,['Physiological condition']
gut barrier,0,1,['Anatomical Structure']
Abnormalities in gut homeostasis,0,1,['Physiological condition']
Biomarker for ASD,0,1,['Biomarker']
Cancer,0,3,['Disease']
Listeria monocytogenes,0,1,['Pathogenic bacterium']
negative psychiatric symptoms,0,2,['Psychiatric Symptoms']
cognition,0,1,['Cognitive Function']
excitement,0,1,['Emotional State']
Psychopathologies in Schizophrenia,0,1,['Psychiatric Disorders']
α-synuclein aggregation in the gut,0,1,['Pathological Process']
TG,0,1,['Lipid Marker']
nutraceuticals,0,1,['Substance']
thyme,0,1,['Plant']
oregano,0,1,['Plant']
Thymus vulgaris,0,1,['Scientific name']
Origanum vulgare,0,1,['Scientific name']
essential oils,0,1,['Substance']
gnotobiotic murine model,0,1,['Model']
colonic microbiota,0,1,['Microbiota']
Diabetes,0,2,['Disease']
coronary artery disease,0,1,['Disease']
Type 2 Diabetes Mellitus,0,2,['Disease']
chronic diseases,0,1,['Disease']
prebiotic effects,0,1,['Effect']
antioxidant effects,0,1,['Effect']
high risk of side effects,0,2,['Risk']
trimethylamine N-oxide,0,1,['Substance']
protein oxidation,0,1,['Process']
mental well-being,0,1,['Health']
mitochondrial function,0,1,['Process']
cardiac contraction,0,1,['Process']
prebiotic actions,0,1,['Effect']
antioxidant actions,0,1,['Effect']
cardiac function,0,1,['Process']
nutraceutical interventions,0,1,['Intervention']
mood,0,1,['Physiological Process']
type-2 diabetes mellitus,0,1,['Disease']
neuronal apoptosis,0,1,['Biological Process']
antioxidant activities,0,1,['Biological Process']
innate immunity,0,2,['Biological Process']
gut homeostasis,0,1,['Biological Process']
cognitive resilience,0,1,['Trait']
psychological resilience,0,1,['Trait']
5-hydroxytryptamine (5-HT) receptors,0,1,['Biological Entity']
brain-derived neurotrophic factor (BDNF) receptors,0,1,['Biological Entity']
antioxidant-related signaling pathways,0,1,['Biological Process']
Zhe Busong decoction,0,1,['Medicine']
Ayurvedic polyherbal medicine,0,1,['Medicine Type']
dried fruits,0,1,['Component']
Psychological Symptoms,0,1,['Symptoms']
promoting resilience,0,1,['Purpose']
stress-induced depression,0,1,['Disease']
treat psychological dysfunction,0,1,['Therapeutic Use']
detrimental consequences,0,1,['Effect']
onset of stress-induced mental health problems,0,1,['Effect']
prevent and treat cognitive impairment,0,1,['Therapeutic Use']
scientific validity,0,1,['Validity Measure']
addressing stress-induced health problems,0,1,['Purpose']
polyphenols,0,1,['Substance']
cognitive and psychological resilience,0,1,['Trait']
stress resilience,0,1,['Trait']
systemic bioavailability,0,1,['Biological Process']
blood brain barrier (BBB) permeability,0,1,['Biological Process']
brain health maintenance,0,2,['Therapeutic Use']
gastrointestinal symptoms,0,1,['Symptom']
GI tract,0,1,['Organ']
postinfection disorders of gut-brain interaction (DGBI),0,1,['Disorder']
IBS,0,1,['Disorder']
early α-synuclein aggregation,0,2,['Pathological Process']
female gender,0,1,['Demographic']
symptomatic COVID-19,0,1,['Condition']
severity of COVID-19,0,1,['Severity']
anosmia,0,1,['Symptom']
development and function of the enteric nervous system,0,1,['Biological Process']
ageusia,0,1,['Symptom']
use of antibiotics,0,1,['Treatment']
hospitalization,0,1,['Medical Procedure']
cholinergic signalling system,0,1,['Biological Process']
presence of mental health factors,0,1,['Condition']
altered gut motility,0,1,['Physiological Mechanism']
visceral hypersensitivity,0,1,['Physiological Mechanism']
gut microbiota dysbiosis,0,1,['Physiological Mechanism']
immune activation,0,1,['Physiological Mechanism']
changes in intestinal permeability,0,1,['Physiological Mechanism']
alterations in the enteroendocrine system,0,1,['Physiological Mechanism']
serotonin metabolism,0,1,['Physiological Mechanism']
substantial healthcare burden,0,1,['Healthcare Impact']
development and function of the gut,0,1,['Biological Process']
gut microbiota profiles,0,1,['Biological Entity']
monoamine neurotransmitters,0,1,['Biological Molecule']
amino acid transmitters,0,1,['Biological Molecule']
persistent GI symptoms beyond 1 month after recovery,0,1,['Symptom']
leading cause,0,1,['Cause']
Subdoligranulum,0,2,"['Microbial Taxon', 'Microorganism']"
Christensenellaceae R-7 group,0,1,['Microorganism']
disability,0,1,['Condition']
morbidity,0,1,['Condition']
mortality,0,1,['Condition']
dysfunction,0,1,['Condition']
Veillonella,0,1,['Microorganism']
brain⁻gut axis,0,4,['Biological System']
drugs,0,1,['Medication']
psychotherapy,0,1,['Therapy']
monounsaturated fatty acids,0,1,['Food']
TC,0,1,['Cholesterol Marker']
brain⁻gut axis health,0,1,['Health Condition']
SFA,0,1,['Food']
simple sugars,0,1,['Food']
prevention,0,1,['Preventive Measure']
therapy,0,1,['Therapeutic Measure']
affective disorders,0,2,['Disease']
systematic review,0,1,['Research Methodology']
controls,0,2,['Control Group']
Social Functioning,0,1,['Psychological Outcome']
vegetables,0,1,['Food']
research quality,0,1,['Research Quality Metric']
anxiety/depression symptom measures,0,1,['Clinical Measurement']
functional analyses,0,1,['Research Methodology']
treatment research,0,1,['Research Field']
Liquid chromatography-mass spectrometry,0,1,['Methodology']
Microbial dysbiosis,0,1,['Condition']
Microbial metabolite biomarkers,0,1,['Metabolite']
Schizophrenia patients,0,2,['Patient Group']
Mental health,0,3,"['Health', 'Health Condition']"
Schizophrenia severity,0,1,['Disease Symptom']
Kyoto Encyclopedia of Genes and Genomes pathway,0,1,['Pathway Database']
Psychiatric clinical symptoms,0,1,['Symptom']
Pathophysiology,0,1,['Disease Pathology']
Human health,0,2,['Health']
Their metabolites,0,1,['Metabolite']
RYGB vs. SG,0,1,['Surgical Procedures']
higher,0,1,['Prevalence Level']
Oscillibacter,0,2,"['Microorganism', 'Microbe']"
smokers,0,2,['Population']
waist circumference,0,1,['Physiological Measurement']
non-smoking patients with AD,0,1,['Population']
health,0,1,['Health Indicator']
oxidative stress,0,2,"['Process', 'Physiological State']"
systemic low-grade inflammation,0,1,['Physiological State']
dysmetabolism,0,1,['Metabolic State']
development of diseases,0,1,['Disease Process']
therapeutic strategy,0,2,"['Therapeutic Method', 'Strategy']"
Prader-Willi syndrome,0,2,['Disease']
metabolic aspects,0,1,['Physiological Process']
mental health aspects,0,1,['Mental Health']
UCG-005,0,1,['Microorganism']
lower,0,1,['Abundance Level']
telomere shortening,0,1,['Biological Process']
aging,0,1,['Biological Process']
inflammatory markers,0,1,['Biological Marker']
reduced likelihood of MDD,0,1,['Disease']
Stool Biobank,0,1,['Repository']
liability for MDD,0,1,['Disease']
depressive-like and anxiety-like behaviours,0,1,['Behaviour']
short chain fatty acids,0,5,['Metabolite']
glutamate,0,1,['Neurotransmitter']
tryptophan,0,1,['Amino Acid']
epinephrine,0,1,['Neurotransmitter']
γ-aminobutyric acid,0,1,['Neurotransmitter']
novel therapeutics,0,1,['Therapeutic Approach']
Nonalcoholic Fatty Liver,0,1,['Disease']
Bacillus licheniformis reducing depressive-like behaviours,0,1,['Effect']
depression- and anxiety-like behaviors,0,2,['Behavior']
intestinal flora diversity,0,1,['Microbial Diversity']
Carbohydrates,0,1,['Chemical Compound']
MCP-1,0,2,['Inflammatory Marker']
IL-17A,0,2,['Inflammatory Marker']
hippocampus,0,4,"['Brain Region', 'brain region']"
brain tissue,0,1,['Anatomical Structure']
body weight,0,1,['Physiological Measurement']
liver fat,0,1,['Physiological Measurement']
Surge in Diabetes,0,5,['Event']
LDL-C,0,1,['Cholesterol Marker']
Recurrent Clostridium Difficile Infection,0,2,['Disease']
systematic reviews,0,1,['Research Methodology']
depressive symptoms,0,2,['Condition']
mood disorders,0,2,"['Condition', 'mental health condition']"
six microbiota taxa,0,1,['Gut Microbiota']
significance,0,1,['Significance']
comprehensive insight,0,1,['knowledge']
children,0,1,['Demographic Group']
physical health,0,1,['Health Aspect']
children with VVS,0,1,['Patient Group']
matched controls,0,1,['Control Group']
16S rRNA gene sequencing,0,1,['Method']
microbial tryptophan metabolism,0,1,['biological process']
independent sample t test,0,1,['Statistical Test']
gut-blood barrier,0,1,['Biological Entity']
clinical symptoms,0,2,['Symptoms']
Pearson correlation test,0,1,['Statistical Test']
Spearman correlation test,0,1,['Statistical Test']
VVS children,0,1,['Patient Group']
discriminative feature,0,1,['Feature']
frequency of syncope,0,1,['Clinical Measure']
systolic pressure reduction,0,1,['Hemodynamic Measure']
diastolic pressure reduction,0,1,['Hemodynamic Measure']
mean pressure drop,0,1,['Hemodynamic Measure']
decline rate,0,2,['Hemodynamic Measure']
diastolic pressure drop,0,1,['Hemodynamic Measure']
hemodynamics,0,1,['Hemodynamic Measures']
development of VVS,0,1,['Medical Condition']
Mann-Whitney U test,0,1,['Statistical Test']
infant microbiota,0,1,['microbiota']
mother's microbiota,0,1,['microbiota']
unrelated mothers' microbiota,0,1,['microbiota']
seeding infant stool microbiota,0,2,['process']
Caesarean delivery,0,1,['delivery mode']
differential infant microbiota composition,0,1,['process']
microbiome composition,0,1,['Biological Process']
colonic microbiome,0,1,['Biological Process']
multiple sclerosis,0,4,"['Disease', 'autoimmune disease']"
neuromyelitis optica,0,1,['Disease']
amyotrophic lateral sclerosis,0,1,['Disease']
alpha synucleinopathies,0,2,['Disease']
reproducibility,0,1,['Process']
comparability,0,1,['Process']
disease,0,1,['Disease']
COVID-19 disease,0,1,['Disease']
bacterial species,0,1,['Bacteria']
strains,0,1,['Bacteria']
effects on host,0,1,['Host']
Inflammatory Gut Milieu,0,1,['Physiological State']
Mucosal Barrier Integrity,0,1,['Physiological Function']
Gut Microbiota Homeostasis,0,1,['Physiological Function']
Exposure to Traumatic Events,0,1,['Event']
Comorbidities,0,3,['Health Condition']
Proinflammatory Milieu,0,1,['Physiological State']
Dysbiotic Gut Microbiota,0,1,['Physiological State']
Gut Homeostasis,0,1,['Physiological Function']
Proinflammatory Gut Environment,0,1,['Physiological State']
Microbiota Dysbiosis,0,1,['Physiological State']
Transepithelial Electrical Resistance,0,3,['Physiological Measurement']
Mucin Homeostasis,0,1,['Physiological Function']
disease group,0,1,['Disease Group']
Stressed Mice,0,1,['Organism']
Lactobacillus Abundance,0,1,['Microbial Abundance']
Immune Changes,0,1,['Physiological Change']
Antidepressant-like Activity,0,2,['Therapeutic Effect']
health trajectory,0,1,['health outcome']
digestion,0,1,['physiological process']
nutrient absorption,0,1,['physiological process']
immune system development,0,1,['physiological process']
inflammatory bowel disease,0,1,['disorder']
neurological conditions,0,1,['disorder']
cognitive function,0,4,"['cognitive process', 'mental process']"
gastrointestinal disorders,0,1,['disorder']
chronic enteropathy,0,1,['disorder']
food allergies,0,1,['disorder']
ulcerative histiocytic colitis,0,1,['disorder']
infant faecal microbiota,0,1,['microbiota']
disease management,0,1,['health outcome']
therapeutic interventions,0,1,['treatment method']
well-being enhancement,0,1,['health outcome']
fecal microbiota signatures,0,2,['Biological Entity']
IBS-D,0,2,['Disease']
brain-gut axis interaction,0,1,['Biological Process']
fecal metagenome-wide sequencing,0,1,['Research Method']
serum metabolomics profiling,0,1,['Research Method']
IBS-D patients,0,2,['Patient Group']
Depression patients,0,1,['Patient Group']
carbohydrate metabolism,0,2,['Biological Process']
neuroactive metabolism,0,1,['Biological Process']
clinical differences,0,1,['Clinical Observation']
brain-gut disorder,0,1,['Disease']
seeding the microbiota,0,1,['process']
health promotion,0,1,['health outcome']
autism spectrum disorder,0,3,"['developmental disorder', 'disorder']"
neurodevelopmental outcomes,0,1,['outcome']
pregnancy,0,2,['pregnancy stage']
risk of autism spectrum disorder,0,1,['disorder']
Neuropsychiatric disorders,0,1,['Disease']
Psychiatric disorders,0,1,['Disease']
Prosocial behavior,0,1,['Behavioral Trait']
Lachnospiraceae family,0,1,['Microbial Taxon']
Attention Deficit Hyperactivity Disorder (ADHD),0,1,['Disease']
Autism Spectrum Disorder (ASD),0,1,['Disease']
Microbiome composition,0,1,['Biological Process']
Mental disorders,0,1,['Disease']
Severity of mental disorders,0,1,['Disease Severity']
Other processes,0,1,['Biological Process']
Specific bacteria,0,1,['Microbial Taxon']
Antimicrobial Responses,0,1,['Physiological Function']
serum metabolism,0,2,['Metabolism']
emotional mood,0,2,['Mood']
fecal microbiota dysbiosis,0,1,['Condition']
psychiatric comorbidities,0,2,['Condition']
glucose homeostasis,0,1,['Physiological Process']
serum metabolome,0,1,['Metabolome']
systemic inflammation,0,2,"['Inflammation', 'Condition']"
Akkermansias,0,1,['Microbe']
Desulfovibrio,0,1,['Microbe']
Depression-like Behavior,0,1,['Behavior']
Functional Microorganisms,0,1,['Organism']
Antidepressant Effects,0,1,['Effect']
Stress-induced Depression,0,1,['Disease']
Fermenting Wheat Germs,0,2,['Process']
Rats,0,1,['Animal']
Understanding gut microbiota,0,3,['Knowledge Domain']
Increased Intestinal Expression of Claudin-2,0,1,['Physiological State']
Increased Intestinal Expression of Epinephrine,0,1,['Physiological State']
Claudin-2 Expression,0,2,['Gene Expression']
Health,0,2,['Physiological State']
Interdependent Effects,0,1,['Physiological State']
gastric pathologies,0,1,['Disease']
ocular Alzheimer's disease,0,1,['Disease']
inflammatory mediators,0,2,"['Substance', 'Biological Entity']"
defensins,0,1,['Substance']
autophagy,0,1,['Biological Process']
vitamin D,0,1,['Substance']
dietary factors,0,1,['Substance']
pathogenetic considerations,0,1,['Concept']
relevant involved genes,0,1,['Gene']
Mild Metabolic Disorders,0,1,['Disease']
"Pathogenesis of complex, polygenic brain disorders",0,1,['Disease Mechanism']
Autoimmune disorders,0,1,['Condition']
Enteropathic celiac disease,0,1,['Condition']
Non-celiac food sensitivities,0,2,['Condition']
Humoral immunity to food antigens,0,1,['Immune Response']
Endothelial barrier permeability,0,1,['Physiological Process']
Translocation of gut bacteria,0,1,['Biological Process']
Inflammatory GI environment,0,1,['Condition']
Activation of complement C1q,0,1,['Biological Process']
Synapses in the brain,0,1,['Anatomical Structure']
Digestion,0,1,['Physiological Process']
Gut permeability,0,1,['Physiological Process']
Behavior,0,1,['Behavior']
Core bacterial compositions,0,1,['Microbial Community']
Inefficient gluten digestion,0,1,['Physiological Process']
Altered phylogenetic compositions,0,1,['Biological Characteristic']
Metabolic Disturbances,0,3,['Condition']
Severity Of Migraine Headache Attacks,0,1,['Medical Condition Aspect']
Increased Gut Permeability,0,2,['Pathological Condition']
type 1 diabetes mellitus,0,1,['Disease']
cognitive functions,0,1,['Biological Process']
modify gut microbiota,0,1,['Biological Process']
depletion of acetate-producing bacteria,0,1,['Biological Process']
cognitive impairment,0,3,"['Disease', 'Condition']"
hippocampal SYP level,0,1,['Biological Marker']
recovery effect,0,1,['Effect']
neuropsychiatric disorders,0,3,['Disease']
gastrointestinal tract,0,2,"['anatomical system', 'Anatomical Structure']"
periodontitis,0,1,['Disease']
brains,0,1,['Anatomical Structure']
Alzheimer's disease,0,4,"['Disease', 'neurodegenerative disease']"
immune system,0,3,"['biological system', 'Biological System', 'Physiological System']"
Highly Diverse Bacterial Communities,0,1,['Microbial Community']
skin inflammation,0,1,['Condition']
serum hormone production,0,1,['Physiological Process']
skin lipids,0,1,['Biochemical']
lipid metabolism-related genes,0,1,['Gene']
gut microbiota richness,0,1,['Microbial Community']
Bacteroidetes to Firmicutes ratio,0,1,['Microbial Ratio']
Staphylococcus abundance,0,1,['Microbial Abundance']
Reactive oxygen species,0,2,"['Chemical', 'Chemical compound']"
Ultraviolet radiation,0,1,['Radiation']
Metals,0,1,['Chemical element']
Thermal regulation,0,1,['Biological process']
Drug uptake,0,1,['Biological process']
Innate immune system functions,0,1,['Biological process']
Redox reactions,0,1,['Chemical process']
Energy transduction,0,1,['Biological process']
human homeostasis,0,1,['Biological Process']
mental health,0,7,"['Health Aspect', 'mental state', 'Condition', 'health aspect']"
Neurological disorders,0,1,['Disease']
Multiple sclerosis,0,1,['Disease']
Mental illnesses,0,1,['Health Condition']
Glucose Tolerance,0,2,['Physiological Process']
HbA1c,0,1,['Biological Marker']
Weight,0,1,['Anthropometric Measure']
Glycemic Control,0,1,['Physiological Process']
pathogenesis of Parkinson's disease,0,1,['Pathogenesis']
clinical picture of Parkinson's disease,0,1,['Clinical Presentation']
significant increase in Bacteroides,0,1,['Microbial Change']
significant decrease in Firmicutes,0,1,['Microbial Change']
significant decrease in Bifidobacteria,0,1,['Microbial Change']
significantly higher Bacteroides,0,1,['Microbial Change']
lower Firmicutes,0,1,['Microbial Change']
Frequency Of Migraine Headache Attacks,0,1,['Medical Condition Aspect']
lower Bifidobacteria,0,1,['Microbial Change']
significant decrease in Lactobacilli,0,1,['Microbial Change']
importance of microbiome identification,0,1,['Research Focus']
treatment of Parkinson's disease,0,1,['Therapeutic Approach']
Influenza virus infection,0,1,['Disease']
Brain structure,0,1,['Anatomy']
Brain function,0,1,['Function']
Immunity,0,2,"['Immune System', 'Biological Function']"
Symptom severity,0,1,['Symptom']
Symptomatic expression,0,2,['Symptom']
Microbiome-targeted interventions,0,1,['Intervention']
Clinical outcomes,0,1,['Outcome']
Gastrointestinal Diseases,0,1,['Medical Condition']
Brain Function,0,3,"['Biological Process', 'Physiological Function']"
Increased Intestinal Epithelial Permeability,0,1,['Pathological Condition']
lower Firmicutes / Bacteroidetes ratio,0,1,['Microbial Ratio']
plants,0,1,['Organism']
microorganisms,0,1,['Organism']
neuroactive compound,0,11,['Chemical']
neuroactive compounds,0,2,['Chemical']
amount of neuroactive compounds,0,1,['Chemical']
profile of neuroactive compounds,0,1,['Chemical']
effects of diet,0,1,['Diet']
food-mood relationship,0,2,['Relationship']
brain development,0,1,['developmental outcome']
behaviour,0,2,"['behavioural outcome', 'behavioral process']"
child internalising behaviour,0,1,['behavioural outcome']
mothers of children with normative behaviour,0,2,['maternal characteristic']
decreased child internalising behaviours,0,1,['behavioural outcome']
GABA,0,5,['neuroactive compound']
acetylcholine,0,4,['neuroactive compound']
Heart,0,1,['Organ']
evaluation of GABA production,0,1,['evaluation']
neuroactive metabolites,0,1,['metabolites']
schizophrenia,0,1,['disease']
diagnosis,0,2,['diagnostic_method']
comparison,0,1,['study_method']
biomarker,0,1,['biomarker']
schizophrenia_patients,0,12,['patient_group']
metabolic_pathway_analysis,0,1,['analysis_method']
Behavioral Deficits,0,1,['Condition']
Stress-related Disorders,0,1,['Condition']
Multi-strain Probiotics Treatment,0,3,['Therapeutic Agent']
Anxiety-like Behavior,0,4,['Behavioral Phenotype']
Depressive-like Behavior,0,4,['Behavioral Phenotype']
Hippocampus,0,3,['Brain Region']
Non-stress Group,0,1,['Control Group']
anti-inflammatory activities,0,1,['activity']
Arteries,0,1,['Organ']
Ovaries,0,1,['Organ']
Almost all cells,0,1,['Cell']
Alzheimer's disease (AD),0,1,['Disease']
Lewy Body Dementia (LBD),0,1,['Disease']
Melanosomes,0,1,['Cellular component']
Apoptosis,0,1,['Biological process']
Energy from electromagnetic radiation,0,1,['Energy']
Energy retained in melanin,0,1,['Energy']
Energy supply of cells,0,1,['Energy']
Inability to sustain immune system defenses,0,1,['Biological process']
Inability to remove plaques,0,1,['Biological process']
Immune system's attempt to eradicate pathogens,0,1,['Biological process']
Immune system's response to pathogens,0,1,['Biological process']
Cells,0,1,['Cell']
major depressive disorders,0,1,['Disease']
Lactobacillaceae,0,1,['Microbial family']
inflammation-related cytokines levels,0,1,['Biological process']
stress-related hormones levels,0,1,['Biological process']
neurotransmitters levels,0,1,['Biological process']
neurotrophins levels,0,1,['Biological process']
depressive behaviors,0,1,['Symptom']
major depressive disorder,0,2,"['Disease', 'disease']"
ATP,0,1,['Energy']
kaempferol,0,1,['Chemical compound']
quercetin,0,1,['Chemical compound']
isorhamnetin,0,1,['Chemical compound']
New avenues for treatment development,0,1,['Therapeutic strategy']
Many diseases,0,1,['Disease']
Healthy cells,0,1,['Cell']
Melanomas,0,1,['Disease']
Melanin levels,0,1,['Substance']
medicine food homology,0,1,['Concept']
subdiaphragmatic vagus nerve,0,1,['Anatomical Structure']
CRC development,0,1,['Disease_Development']
Research,0,8,['Research_Field']
Publications,0,2,['Publication']
Bibliometric analysis,0,1,['Analysis_Method']
Knowledge-map analysis,0,1,['Analysis_Method']
Inflammatory bowel disease,0,1,['Disease']
Fusobacterium nucleatum,0,1,['Microorganism']
Long-chain fatty acids,0,1,['Biochemical_Substance']
Ulcerative colitis,0,1,['Disease']
Bile acids,0,1,['Biochemical_Substance']
Resistant starch,0,1,['Dietary_Substance']
analyzing gut microbiome data,0,1,['Analysis']
analyzing gut microbial community composition,0,1,['Analysis']
developing classification model,0,1,['Model']
CUMS Model Rats,0,1,['Organism']
statistically significant bacteria,0,1,['Bacteria Data']
76.82% accuracy,0,1,['Accuracy']
highest classification accuracy,0,1,['Accuracy']
third hierarchical level,0,1,['Pathway Level']
model accuracy,0,1,['Accuracy']
nutritional needs,0,1,['Physiological Need']
psychiatric symptoms,0,2,['Symptom']
neurotransmitter levels,0,2,['Physiological Process']
mental disorders,0,9,"['Disease', 'Condition']"
psychotic disorders,0,1,['Disease']
multichannel sensing pathways,0,1,['biological pathways']
neuroanatomy,0,1,['biological structure']
HPA axis,0,1,['biological system']
immune routes,0,1,['biological pathways']
microbially-derived neurotransmitters,0,1,['biological molecules']
validating classification model,0,2,['Validation']
Chronic Stress-induced Anhedonia,0,1,['Condition']
Patients with Major Depressive Disorder,0,1,['Patient Group']
Depressive Symptoms,0,1,['Symptoms']
Neurometabolic Alterations,0,1,['Biological Change']
Alleviates Anhedonic Behaviors,0,1,['Behavioral Change']
Regulates Metabolite Concentrations,0,1,['Biochemical Process']
Reduces Serotonin Levels,0,1,['Neurotransmitter Change']
Restores Htr1a Expression,0,1,['Gene Expression Change']
Medial Prefrontal Cortex,0,1,['Brain Region']
Anhedonic Behavior,0,1,['Behavioral Symptom']
Etiology,0,2,"['Disease Cause', 'Concept']"
Short-Chain Fatty Acid Producing Bacteria,0,1,['MicrobialTaxon']
Gut Microbiome Alteration,0,1,['BiologicalChange']
Gut Microbiome Differences,0,1,['BiologicalChange']
Parkinson's Disease,0,1,['Disease']
relative abundance of microbiome populations,0,2,['Biological Process']
bidirectional communication system,0,1,['communication system']
cognitive brain areas,0,1,['brain areas']
neuronal activity,0,1,['biological process']
communication between gut-resident bacteria and brain,0,1,['communication process']
gut microorganisms,0,1,['microbial entities']
gut physiology,0,2,"['biological process', 'physiological process']"
neuronal disorders,0,2,['disease states']
imbalance in gut microbiota,0,3,['microbial imbalance']
treatment of neuronal disorders,0,3,['disease treatment']
diseases of the GI tract,0,1,['gastrointestinal diseases']
brain function,0,2,"['biological process', 'brain activity']"
anxiety disorders,0,1,['mental disorder']
modulation of gut microbiota,0,1,['microbial modulation']
brain/mental-health-related disease,0,1,['mental health disease']
blood levels of metabolites,0,3,['Physiological Process']
Individuals with Parkinson's Disease,0,1,['PatientPopulation']
acute and chronic insomnia,0,1,['medical condition']
lower microbial richness and diversity,0,1,['biological characteristic']
depletion of anaerobes,0,1,['biological characteristic']
depletion of SCFA-producing bacteria,0,1,['biological characteristic']
expansion of potential pathobionts,0,1,['biological characteristic']
acute insomnia,0,2,['medical condition']
chronic insomnia,0,2,['medical condition']
self-reported sleep quality,0,1,['assessment metric']
plasma IL-1β,0,1,['biomarker']
auxiliary diagnosis of insomnia,0,1,['diagnostic tool']
therapeutic targets,0,1,['treatment option']
gut-brain axis disruption,0,1,['Biological Process']
host homeostasis,0,1,['Biological State']
systemic disorders,0,1,['Disease']
sleep balance,0,1,['Physiological Process']
intestinal and brain barriers,0,1,['biological structures']
higher risk of insomnia,0,6,['Health Outcome']
neurotransmitters,0,5,"['Neurotransmitter', 'biochemical molecule']"
indoles,0,1,['biochemical molecule']
bile acids,0,1,['biochemical molecule']
choline metabolites,0,1,['biochemical molecule']
lactate,0,1,['biochemical molecule']
vitamins,0,1,['biochemical molecule']
depressive behavior,0,1,['behavioral phenotype']
central receptors,0,1,['biological entity']
neural mediators,0,1,['biological entity']
endocrine mediators,0,1,['biological entity']
immune mediators,0,1,['biological entity']
epigenetic regulation,0,1,['biological process']
histone acetylation,0,1,['biological process']
novel therapeutic strategies,0,1,['therapeutic strategy']
second genome,0,1,['Concept']
inflammatory disorders,0,1,['disease category']
autoimmune disorders,0,1,['disease category']
metabolic disorders,0,1,['disease category']
behavioral disorders,0,1,['mental health condition']
cognitive disorders,0,1,['mental health condition']
autism-spectrum disorders,0,1,['mental health condition']
stress-related disorders,0,1,['mental health condition']
pain-related disorders,0,1,['health condition']
nutrients,0,1,['biological molecules']
microbiome,0,1,['biological system']
intestinal system,0,1,['biological system']
epithelium-enteric nervous system,0,1,['biological system']
endocrine system,0,1,['biological system']
Gut microbial metabolism,0,2,['Biological process']
Pathophysiology of diseases,0,1,['Pathophysiological process']
mental illnesses,0,1,['disease']
behavior,0,1,['biological process']
microglial states,0,1,['Cellular State']
beneficial effects of prebiotics,0,1,['Therapeutic Effect']
expansion of protective disease-associated macrophage (DAM) subsets,0,1,['Cellular Process']
pathogenic microglial states,0,1,['Cellular State']
reduced homeostatic responses,0,1,['Cellular Process']
increased pro-inflammatory signaling,0,1,['Cellular Process']
α-synuclein pathology,0,1,['Pathological Process']
α-synuclein aggregation,0,2,['Pathological Process']
motor deficits,0,2,['Symptom']
microglial function,0,1,['Cellular Process']
microglia activation,0,1,['Cellular Process']
healthy controls,0,1,['Control Group']
short-chain fatty acids,0,3,"['Substance', 'biochemical molecule']"
motor symptoms,0,2,['Symptom']
neurodegeneration,0,2,['Pathological Process']
health-correlated profile,0,1,['Physiological State']
Fusobacterium,0,1,['Microbial Taxon']
Critical care,0,2,['Clinical Outcome']
Worse clinical outcomes,0,1,['Clinical Outcome']
epilepsy,0,1,['Disease']
migraine,0,1,['Disease']
human body,0,1,['Organism']
pathophysiology,0,2,"['Biological Process', 'biological process']"
discovery of the microbiota-gut-brain axis,0,1,['Discovery']
microbiota-gut-brain axis studies,0,1,['Research Study']
hypnotic effects,0,4,['Effect']
sleep latency,0,2,['Physiological Parameter']
sleep disturbances,0,1,['Condition']
distinct genetic characteristics,0,1,['Genetic Feature']
sheet-like EPS structure,0,1,['Structural Feature']
EPS structure,0,1,['Structural Feature']
literature reference,0,1,['Concept']
hypnotic effect,0,1,['Effect']
Polycystic Ovary Syndrome (PCOS),0,1,['Disease']
Progression of PCOS,0,1,['Disease Progression']
Profiling Fecal Microbiota,0,1,['Biological Process']
Gene Expression Profiling,0,1,['Biological Process']
Ruminococcus torques,0,1,['Microbial Species']
Coprococcus comes,0,1,['Microbial Species']
Megasphaera elsdenii,0,1,['Microbial Species']
Acidaminococcus intestini,0,1,['Microbial Species']
Barnesiella viscericola,0,1,['Microbial Species']
Differential Expressed Genes (DEGs),0,1,['Genetic Entity']
Signal Transduction Pathways,0,1,['Biological Process']
Endocrine and Metabolic Diseases,0,1,['Disease Category']
Lipid Metabolism Pathways,0,1,['Biological Process']
Neurodegenerative Diseases,0,1,['Disease Category']
recovery time,0,1,['Physiological Parameter']
Depression-like Behaviors,0,1,['Behavior']
Neurotransmitter Levels,0,2,['Physiological Measure']
Gut Microbiota Structure,0,1,['Physiological Measure']
Amino Acid Metabolic Functions,0,1,['Physiological Measure']
Chronic Restraint Stress,0,1,['Condition']
Neurobehavioral Deficits,0,1,['Condition']
Gut Barrier Deficits,0,1,['Condition']
Colonic Permeability,0,1,['Physiological State']
ZO-1,0,1,['Protein']
Claudin,0,1,['Protein']
Occludin,0,1,['Protein']
IL-1β,0,2,"['Protein', 'Inflammatory Marker']"
IL-6,0,1,['Protein']
Odoribacter,0,1,['Microbe']
Tryptophan Synthesis,0,1,['Metabolic Pathway']
Faecalibacterium prausnitzii,0,1,['Microbial Taxon']
Mental Health,0,4,"['Health Aspect', 'Psychological Outcome', 'Health Condition']"
alterations in the gut microbiome,0,1,['effect']
Parkinsonian pathology,0,1,['pathology']
degeneration of dopaminergic neurons,0,1,['biological process']
α-synuclein accumulation,0,1,['biological process']
endolysosomal deficits,0,1,['biological process']
drinking water,0,1,['environmental medium']
short-chain fatty acid production,0,1,['metabolic process']
lactic acid,0,1,['metabolite']
opportunistic pathogens,0,1,['microbial species']
Gut microbiota disturbances,0,1,['Biological Process']
Metabolic health,0,1,['Physiological Function']
Muscular health,0,1,['Physiological Function']
Microbiota diversity,0,1,['Biological Process']
Lachnospiraceae NK4A136 group,0,1,['Microbial Taxon']
Inositol Degradation,0,1,['Metabolic Pathway']
MDD patients,0,3,['Population']
MDD group,0,1,['Population']
HAMD scores,0,1,['Clinical Data']
area under the receiver operating characteristic curve of 0.890,0,1,['Performance Metric']
MDD patients from HCs,0,1,['Population']
sleep,0,1,['Condition']
Lactobacillus reuteri NK33,0,1,['Bacteria']
Bifidobacterium adolescentis NK98,0,1,['Bacteria']
anxiety symptoms,0,1,['Condition']
sleep quality,0,1,['Condition']
serum interleukin-6 levels,0,1,['Biomarker']
Bifidobacteriaceae,0,1,['Bacteria']
Lactobacillacea,0,1,['Bacteria']
intestinal bleeding,0,1,['Condition']
iron deficiency,0,1,['Condition']
Immune System Pathways,0,1,['Biological Process']
Fe,0,1,['Substance']
rhEPO,0,1,['Substance']
subcutaneous inoculation of CT-26,0,1,['Procedure']
i.p. oxaliplatin,0,1,['Procedure']
blood enrichment,0,1,['Effect']
antitumor activity,0,1,['Activity']
decreased relative abundances of Lachnospiraceae,0,1,['Effect']
decreased relative abundances of Odoribacter,0,1,['Effect']
Helicobacter,0,1,['Bacteria']
Lactococcus,0,1,['Bacteria']
Alloprevotella,0,1,['Bacteria']
Escherichia-Shigella,0,1,['Bacteria']
Ruminococcaceae_UCG-014,0,1,['Bacteria']
smaller tumor volume,0,1,['Effect']
theoretical basis,0,1,['Concept']
chemotherapy-induced myelosuppression,0,1,['Condition']
Cell membranes,0,1,['Biological structure']
Iron content,0,1,['Chemical']
Cytochrome c protein,0,1,['Protein']
Alpha-synuclein oligomers,0,1,['Protein']
Alpha-synuclein fibrils,0,1,['Protein']
Urate metabolism,0,1,['Biological process']
Erythrocytes,0,1,['Cell type']
Lymphocytes,0,1,['Cell type']
Desulfovibrionaceae,0,1,['Taxonomic family']
Enterobacteriaceae,0,2,"['Taxonomic family', 'Bacteria']"
Hydrogen sulfide-producing bacteria,0,1,['Organism']
deficits in social and communicative behaviors,0,1,['Behavior']
repetitive patterns of behaviors,0,1,['Behavior']
0.1% to 1.8% of the global population,0,1,['Population statistic']
more frequent gastrointestinal (GI) complaints,0,1,['Symptom']
biomarkers,0,2,['Biomarker']
gut microbiota as biomarkers,0,1,['Biomarker']
Boruta algorithm,0,1,['Algorithm']
Random Forests (RF),0,1,['Algorithm']
29 healthy controls (HCs),0,1,['Population']
26 MDD patients,0,1,['Population']
MiTBamp,0,1,['Pathway']
pathogenesis of major depressive disorder (MDD),0,2,['Disease']
GI symptoms,0,4,['Symptom']
tryptophan pathway differences,0,1,['Finding']
taxonomic differences,0,1,['Finding']
multiple different strains and concentrations,0,1,['Characteristic']
management of GI or behavioral symptoms,0,1,['Condition']
GI symptoms and behavior,0,1,['Outcome']
alleviating GI or behavioral symptoms,0,1,['Condition']
significant reduction in anti-sociability scores,0,1,['Outcome']
behavioral issues,0,1,['Condition']
gut microbiota differences,0,1,['Finding']
